8 results about "Cowpox virus" patented technology

The invention provides a novel vaccine based on an adenovirus vector and application thereof. According to the present invention, the suitable monkey pox virus gene is selected for the first time, and is efficiently integrated with the chimpanzee virus vector (AdC68) to prepare the ideal virus vaccine, and the ideal virus vaccine is suitable for nasal cavity immunization and muscle immunization, and has good nasal cavity immunization effect. The novel monkey pox vaccine can be effectively used for prevention and control of monkey pox virus and vaccinia virus infection, and the two types of viruses are considered.

The present invention relates to a primer set, composition, kit for the detection of vaccinia virus for the detection and quantification of vaccinia virus and an analysis method using the same, and the primer set for the detection of vaccinia virus has a shorter analysis period and superior sensitivity and specificity compared to the conventional virus quantitation method, so that when real-time PCR applied to such a primer set is performed, it is possible to detect and quantify vaccinia virus more quickly and accurately in real time.

This invention relates to the field of biomedical engineering technology, and provides the application of striatin interacting protein (STRIP) inhibitors in the preparation of anti-tumor drugs, recombinant vectors of STRIP inhibitors and their application in the preparation of anti-tumor drugs, and anti-tumor pharmaceutical compositions in which STRIP inhibitors or recombinant vectors of STRIP inhibitors are used as active components. This invention aiming at STRIP inhibition can be used to prepare viral drugs for tumor treatment, in particular when it is recombined with vaccinia viruses to form recombinant vectors, which combine the advantages of STRIP inhibitors and vaccinia viruses. The invention provides a new target for viral therapy of tumor and has a broad clinical application prospect.

The invention discloses an application of diphyllin in preparation of drugs for inhibiting poxvirus and preventing or treating poxvirus infection, the poxvirus is common orthopoxvirus poxvirus, the poxvirus comprises vaccinia virus (VACV), vaccinia virus (CPXV) and rabbit poxvirus mucinoma virus (MYXV), the content of diphyllin is in a range of 1.25-2.5 [mu] M / mL, and the content of diphyllin is in a range of 1.25-2.5 [mu] M / mL. The compound has a remarkable inhibiting effect on infection of poxvirus family members such as CPXV, is expected to be used as a medicine for preventing and treating infection of CPXV and other poxviruses, and has important significance on prevention and control of diseases related to poxvirus infection.

The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have neutralizing or cross-neutralizing activity against poxvirus, in particular against monkeypox virus, vaccinia virus and cowpox virus. The invention relates also to the use of such monoclonal antibodies or antigen binding portion thereof in therapy, prophylaxis and diagnosis of poxvirus, in particular monkeypox virus, vaccinia virus and cowpox virus dependent diseases.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

This invention discloses an engineered probiotic outer membrane vesicle vaccine co-expressing multiple antigens of monkeypox virus, its preparation method, and its application. The outer membrane vesicle vaccine is based on... lpxm Using the gene-deleted probiotic Escherichia coli Nissle 1917 as the host, ABM@OMV was constructed by genetically engineering and co-expressing and displaying three key monkeypox virus antigens, A9R, B6R, and M1R, on the surface of its secreted outer membrane vesicles. Leveraging the natural adjuvant and highly efficient mucosal delivery characteristics of OMV, combined with a multi-antigen synergistic strategy, nasal immunization can simultaneously activate strong systemic humoral immunity (high-titer neutralizing IgG) and cellular immunity (CD4+). + / CD8 + T cells are involved in the vaccine, which induces high levels of specific sIgA antibodies in the respiratory and distal genital tract mucosa, forming an effective immune barrier. Challenge experiments showed that the vaccine completely protects mice from lethal doses of vaccinia virus, significantly reduces tissue damage, and provides a novel solution for preventing monkeypox virus transmission via mucosa.

Provided is pharmaceutical use of a nucleoside compound, specifically use of compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing or treating an infectious disease of orthopoxvirus. The compound represented by formula (I) has a significant inhibitory effect on a vaccinia virus, a monkeypox virus, a cowpox virus, and a smallpox virus.